SEOUL: South Korean drugmaker Samsung Biologics plans to add a mRNA vaccine production line at its facility in Songdo, 30 kilometres southwest of Seoul, by the first half of 2022. Messenger RNA (mRNA) vaccines are known for their safety and fast scalability in manufacturing, the company said …
Recent Posts
Most Popular
Morgan Stanley widens gap as banks’ wealth units add US$5 trillion
MORGAN Stanley’s record quarter in wealth management capped a banner period for one of Wall Street’s most-profitable businesses.